ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Triethylamine → 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide

HRID 1992050
印刷

反応式

HRID 1992050 の反応式
Cl.Cl.[CH3:3][C:4]1[N:8]([CH:9]2[CH2:15][CH:14]3[N:16]([CH2:17][CH2:18][C:19]4([C:25]5[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=5)[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]4)[CH:11]([CH2:12][CH2:13]3)[CH2:10]2)[C:7]2[CH:31]=[CH:32][CH:33]=[CH:34][C:6]=2[N:5]=1.[Cl:35][C:36]1[CH:37]=[C:38]([CH:42]=[CH:43][C:44]=1[S:45](=[O:48])(=[O:47])[NH2:46])C(O)=O.C(N(CC)CC)C.CN([C:59]([O:63]N1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C.C(Cl)Cl>[Cl:35][C:36]1[CH:37]=[CH:38][C:42]([C:59]([N:22]2[CH2:21][CH2:20][C:19]([CH2:18][CH2:17][N:16]3[CH:14]4[CH2:13][CH2:12][CH:11]3[CH2:10][CH:9]([N:8]3[C:7]5[CH:31]=[CH:32][CH:33]=[CH:34][C:6]=5[N:5]=[C:4]3[CH3:3])[CH2:15]4)([C:25]3[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=3)[CH2:24][CH2:23]2)=[O:63])=[CH:43][C:44]=1[S:45]([NH2:46])(=[O:47])=[O:48]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 4

HCID 8471TriethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 470031394-(Aminosulfonyl)-3-chlorobenzoic acidHCID 686757782-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride

生成物 1

HCID 54584060
2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide
収率 47%

試薬・触媒・溶媒 2

HCID 6228Dimethylformamide溶媒HCID 6344Dichloromethane溶媒

実験手順

To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (200 mg, 0.4 mmol) in DMF (8 mL) was added 3-chloro-4-sulfamoylbenzoic acid (94 mg, 0.4 mmol), triethylamine (166 μL, 1.2 mmol) and HATU (152 mg, 0.4 mmol). The resulting mixture was stirred at ambient temperature for 3 hours before being diluted with methylene chloride (50 mL). The reaction was then washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide as amorphous solid (120 mg, 47%). 1H NMR (300 MHz, DMSO-d6) δ 7.87-7.71 (m, 3H), 7.57 (s, 1H), 7.50-7.47 (m, 2H), 7.38-7.33 (m, 4H), 7.24 (s, 1H), 7.14-7.06 (m, 2H), 4.49 (m, 1H), 3.98 (m, 1H), 3.42-3.23 (m, 5H), 3.06-3.00 (m, 1H), 2.43 (s, 3H), 2.39-2.22 (m, 2H), 2.17-2.08 (m, 2H), 1.92-1.76 (m, 10H), 1.58-1.56 (br, 2H). HRMS m/z (M+H)+ calcd: 646.2619; obsd: 646.2610.

後処理

  1. washThe reaction was then washed with saturated sodium bicarbonate solution
  2. dry with materialThe organic phase was dried over anhydrous sodium sulfate
  3. customAfter evaporation of the solvent
  4. customthe crude product was purified by flash chromatography on silical gel
  5. washeluting with a gradient of 0-10% methanol in ethyl acetate

出典と根拠

ORDレコード
ord-4310131b4c0a4995abf71171cfbc31dc
出典データセット
uspto-grants-2010_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07645771B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート